Proving the principle: dendritic cell-based vaccines in urogenital cancers

Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

Current immunotherapeutic approaches in pancreatic cancer

Immunotherapy in human glioblastoma

HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy

Immunotherapy for prostate cancer: biology and therapeutic approaches

Pulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?

Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).